Intravesical bacillus Calmette-Guérin has been the standard of care for high-risk non-muscle-invasive bladder cancer for 40 years. It remains one of the most successful immunotherapies ever used. Bacillus Calmette-Guérin shows superior efficacy to alternative intravesical treatments, and has an established role in reducing both recurrence and progression in non-muscle-invasive bladder cancer. It remains relatively safe, and has acceptable tolerability of both local and systemic side-effects. The present review provides insights into the role of bacillus Calmette-Guérin compared with alternative treatments both in primary and refractory settings.
International journal of urology : official journal of the Japanese Urological Association. 2017 Jul 25 [Epub ahead of print]
Manmeet Saluja, Peter Gilling
Department of Urology, Auckland City Hospital, Auckland, New Zealand., Department of Urology, Tauranga Hospital, Tauranga, New Zealand.